Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LASEPR siRNA
- Development stage
- Preclinical
- Lead developer
- Shiga University of Medical Science
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
LASEPR siRNA is a small interfering RNA (siRNA) designed to silence the expression of the lung cancer-associated serum protein 1 receptor (LASEPR). LASEPR is a cell-surface receptor that interacts with its ligand, LASEP1 (lung cancer-associated serum protein 1), a secreted protein frequently overexpressed in various histological types of lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The interaction between LASEP1 and LASEPR promotes cancer cell growth and mobility through autocrine and paracrine signaling pathways. Research has demonstrated that the suppression of LASEPR expression via siRNA leads to the inhibition of lung cancer cell growth in vitro. This identifies the LASEP1-LASEPR signaling axis as a potential therapeutic target for the development of novel molecular therapies for lung malignancies.
- Other names
- siRNA against LASEPRLASEPR-targeting siRNA
02
Targets
LASEPR (Lung cancer-associated serum protein 1 receptor)
Beyond the preview
Go deeper on LASEPR siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LASEPR siRNA.